Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review. Issue 9 (2nd September 2021)

• Record Type: Journal Article
• Authors: Avedissian, Sean N.; Rhodes, Nathanial J.; Shaffer, Christopher L.; Tran, Lan; Bradley, John S.; Le, Jennifer
• Is Part Of: Expert review of anti-infective therapy. Volume 19:Issue 9(2021)
• Page Start: 1107
• Page End: 1116
• Publication Date: 2021-09-02
• Subjects: Staphylococcus aureus -- mrsa -- antibiotics -- pediatrics -- treatment; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2021.1886923
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Introduction : Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), remains a significant pathogen in children. Despite evidence of decreasing prevalence, MRSA bacteremia has been closely associated with complications, including certain infections (i.e. musculoskeletal and endovascular) linked to increased treatment failures. Areas covered : This expert review summarized recent published literature on the role of treatment, dosing and administration of antibiotics used to combat serious S. aureus infections in children. The pertinent antibiotics presented were vancomycin, oxazolidinones, semi-synthetic glycopeptides, daptomycin, tigecycline, novel cephalosporins, fosfomycin and lefamulin. Vancomycin has been the most commonly used antibiotic in empiric therapy for serious MRSA infection, with new key recommendations emphasizing a different approach to dosing and therapeutic monitoring. For other antibiotics, data remain limited or clinical trials are underway. Expert opinion : MRSA remains a significant pathogen in the pediatric population. As numerous therapeutic agents are available, many agents have limited data on usage in pediatric patients. Future studies require pharmacokinetic, safety and efficacy studies in pediatric patients to ensure appropriate therapeutic treatment and outcomes. Phage therapy has been used to treat deep-seated MRSA infections and is an emerging investigational treatment option.